Liru Wang

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Superior 12-month progression-free survival with frontline DVd versus VRd in patients with newly diagnosed multiple myeloma: a multicenter propensity score-matched analysis.

Superior 12-month progression-free survival with frontline DVd versus VRd in patients with newly diagnosed multiple myeloma: a multicenter propensity score-matched analysis.

Journal: Journal of translational medicine

Published: May 24, 2026

Risk stratification, treatment patterns and survival outcomes in newly diagnosed multiple myeloma patients: A real-world analysis from the Chinese Myeloma Committee.

Risk stratification, treatment patterns and survival outcomes in newly diagnosed multiple myeloma patients: A real-world analysis from the Chinese Myeloma Committee.

Journal: British journal of haematology

Published: February 11, 2026

Primary hypertrophic osteoarthropathy complicated with myelofibrosis and compound heterozygous SLCO2A1 mutations: a case report and review of literature.

Primary hypertrophic osteoarthropathy complicated with myelofibrosis and compound heterozygous SLCO2A1 mutations: a case report and review of literature.

Journal: Frontiers in oncology

Published: December 20, 2025

Tandem Versus Single Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma in the Era of Novel Agents: A Real-World Study of China.

Tandem Versus Single Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma in the Era of Novel Agents: A Real-World Study of China.

Journal: Cancer medicine

Published: October 30, 2024

Macrofocal multiple myeloma in the era of novel agents in China.

Macrofocal multiple myeloma in the era of novel agents in China.

Journal: Therapeutic advances in hematology

Published: September 01, 2024

Tucidinostat Combined with Bortezomib, Liposomal Doxorubicin, and Dexamethasone in Multiple Myeloma Treatment.

Tucidinostat Combined with Bortezomib, Liposomal Doxorubicin, and Dexamethasone in Multiple Myeloma Treatment.

Journal: Acta haematologica

Published: August 07, 2024

Characteristics and outcomes of COVID-19 in patients with plasma cell dyscrasias during the first Omicron wave in Beijing since December 2022: a retrospective study at a National Clinical Research Center for Hematologic Disease.

Characteristics and outcomes of COVID-19 in patients with plasma cell dyscrasias during the first Omicron wave in Beijing since December 2022: a retrospective study at a National Clinical Research Center for Hematologic Disease.

Journal: Annals of hematology

Published: April 18, 2023

Treatment patterns and a prognostic scoring system for elderly acute myeloid leukemia patients: a retrospective multicenter cohort study in China.

Treatment patterns and a prognostic scoring system for elderly acute myeloid leukemia patients: a retrospective multicenter cohort study in China.

Journal: Cancer biology & medicine

Published: August 27, 2021

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.

Journal: Oncoimmunology

Published: March 20, 2018

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients.

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients.

Journal: Blood cancer journal

Published: November 25, 2017

Showing 1-10 of 10

Last Updated: 09/26/2026